Search research articles
Contact Us
Filters
Showing results (211-220 of 230) with videos related to
Page
of 23
Sort By:
Cell
|
March 18, 2025
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs
Yong Jiang, Anran Dai, Yuwei Huang, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Chinese Clinical Oncology
|
May 12, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Annals of Translational Medicine
|
January 7, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai, Jiani Hu, Allison Betof Warner, et al.
Therapeutic Advances in Medical Oncology
|
July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
Jun Wang, Bicheng Zhang, Ling Peng, et al.
Nature Communications
|
July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newell, Yan Kong, James S Wilmott, et al.
Eclinicalmedicine
|
November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine
|
April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 230) with videos related to
Sort By:
Page
of 23
Cell
|
March 18, 2025
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs
Yong Jiang, Anran Dai, Yuwei Huang, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Chinese Clinical Oncology
|
May 12, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Annals of Translational Medicine
|
January 7, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai, Jiani Hu, Allison Betof Warner, et al.
Therapeutic Advances in Medical Oncology
|
July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
Jun Wang, Bicheng Zhang, Ling Peng, et al.
Nature Communications
|
July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newell, Yan Kong, James S Wilmott, et al.
Eclinicalmedicine
|
November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Eclinicalmedicine
|
April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Page
of 23